Explore how thrombin generation assays (TGA), FXI inhibitor testing, and translational biomarker strategies enable smarter dose selection, improved outcomes, and optimized global clinical trials.
MLM Medical Labs and Amprion announce a strategic collaboration to expand access to IVDR-compliant alpha-synuclein biomarker testing for clinical trials in Europe.
Explore how thrombin generation assays (TGA), FXI inhibitor testing, and translational biomarker strategies enable smarter dose selection, improved outcomes, and optimized global clinical trials.
Flow cytometry remains a cornerstone technology for multidimensional cellular analysis in clinical research. As biomarker strategies evolve, its applications continue to expand across therapeutic areas—from
At MLM, we deliver high-performance, fully customizable immunoassay solutions designed to meet the complex demands of modern preclinical and clinical trials. As a global specialty
MLM Medical Labs launches a new E-Requisition solution designed to improve data quality, reduce sample-related queries, and support faster clinical trial timelines.
Receptor Occupancy Analysis for Clinical Trials: Powering Precision with Flow Cytometry At MLM Medical Labs, our flow cytometry services include advanced receptor occupancy analysis for
Unlocking Consistency in Global Clinical Trials In global clinical trials, data consistency is critical. Variability between sites can compromise biomarker analysis, delay decision-making, and create
MLM’s library of nearly 1000 validated assays were developed for diabetes studies – a crucial cretieria for selecting the right Central Lab in metabolic-related clinical trials.
Cytespace Africa Laboratories, an MLM company, has launched in-region Next-Generation Sequencing (NGS) capabilities to eliminate delays in African clinical trials. The new platform enables faster, more precise genomic insights—particularly for infectious diseases like tuberculosis—by delivering critical resistance and safety data directly within Africa.
